The introduction of prostate-specific antigen (PSA) screening and an increase in prostate biopsy samples from 6 to 12 both resulted in a substantial rise in early-stage PCa diagnoses [9,10], indicating an essential need for higher diagnostic accuracy and more precise malignancy differentiation in early cancer detection [11]. The gene discussed is KLK3; the disease is cancer.